Cooley M&A

OCTOBER 19, 2022

Cooley’s M&A practice has been busy amid the typically slower summer wind down. Steaming through the third quarter, Cooley’s deal flow put us at the top of the Bloomberg, Mergermarket and Refinitiv Q3 M&A league tables. On August 16, 2022, the Inflation Reduction Act was signed into law.

M&A 69

M&A Initial Public Offering Pharmaceutical Medical 69

The Harvard Law School Forum

OCTOBER 19, 2022

Posted by Ian Nussbaum, Bill Roegge, and Meredith Klionsky, Cooley LLP , on Wednesday, October 19, 2022 Editor's Note: Ian A. The rise of founder-led, venture capital-backed companies in recent years has coincided with a surge of companies implementing dual-class share structures in connection with their initial public offerings.

M&A 103

M&A IPO Shares Stock 103

Cooley M&A

JANUARY 25, 2023

Although 2022 saw a general decline in M&A activity in the life sciences industry compared to 2021’s frenetic pace (when deal volume was up 52% from 2020 ), life sciences deal flow in 2022 on balance remained strong despite the headwinds. Let’s dig in. Let’s dig in.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Cooley M&A

SEPTEMBER 16, 2022

The rise of founder-led, venture capital-backed companies in recent years has coincided with a surge of companies implementing dual-class share structures in connection with their initial public offerings. In a small number of cases, a class of common stock is offered to the public that has no voting rights at all.

M&A 59

M&A IPO Shares Mergers and Acquisitions 59

Cooley M&A

JANUARY 23, 2024

In a subdued year for global M&A, deal-making in the life sciences industry came in waves, with a busy fourth quarter generating cautious optimism heading into 2024. Big pharma dominated life sciences M&A, with more than two-thirds (69%) of M&A investment coming from big pharma, compared to just 38% in 2022.

M&A 52

M&A Mergers and Acquisitions Acquisitions Pharmaceutical 52

OfficeHours

AUGUST 20, 2023

Once improved, the exit can then take place, usually in the form of another sale or an Initial Public Offering (IPO), both of which are usually under the advice of an investment bank. Written by a Top OfficeHours Private Equity Coach Is PE a Good Fit for you? Strategic thinking skills are essential.

Private Equity 130

Private Equity Equities Investment Banking Finance 130

MergersCorp M&A International

JULY 5, 2024

Convertible bonds are a type of security that offers a steady stream of income but also holds the potential for capital appreciation in the form of a stock. Convertible Bonds or CBs are a very attractive investment that offers a several advantage for investors. However, that, CBs carry risks as well.

Debt 52

Debt Stock Initial Public Offering Capital 52